Develops an investigational siRNA-based therapy targeting the root cause of preterm preeclampsia, a life-threatening pregnancy complication. This approach aims to provide safe, evidence-based, and affordable treatment options, improving maternal and neonatal health outcomes globally.
Funding
$126.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Preterm preeclampsia, a severe pregnancy complication, lacks effective therapies that target the underlying biological mechanisms, leading to significant risks for both mother and child. Current treatments primarily manage symptoms rather than addressing the root cause of the disease. This results in limited options for preventing disease progression and improving maternal and neonatal outcomes.
Solution
Comanche Biopharma is developing CBP-4888, an investigational siRNA-based therapeutic designed to address a root cause of preterm preeclampsia by targeting sFlt1. The drug aims to reduce the levels of sFlt1, a protein implicated in the pathogenesis of the disease, thereby restoring the balance of angiogenic factors necessary for healthy placental function. By intervening at the molecular level, CBP-4888 has the potential to prevent or delay the progression of preterm preeclampsia, reducing the need for premature delivery and improving overall pregnancy outcomes. The company's mission is to make evidence-based and affordable therapies globally accessible, ensuring safer pregnancies for women and their babies. CBP-4888 has been granted Orphan Drug Designation by the European Medicines Agency (EMA) and Innovation Passport designation by the U.K. Innovative Licensing and Access Pathway (ILAP).
Target Audience
The primary target audience includes pregnant women at risk of or diagnosed with preterm preeclampsia, as well as obstetricians and maternal-fetal medicine specialists seeking targeted therapies to improve pregnancy outcomes.
Features
- siRNA-based therapy targeting soluble fms-like tyrosine kinase-1 (sFlt1)
- Designed to restore angiogenic balance in the placenta
- Investigational drug for preterm preeclampsia
- Potential to prevent or delay disease progression
- Orphan Drug Designation by the EMA
- Innovation Passport designation by the U.K. ILAP